The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.
This is the first approval in the small cell lung cancer space in nearly two decades.
Caring for a young person with cancer can be a challenge, explains Nancy Bell.
In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.
Clinical trials are starting to focus more on the tumor's genetic makeup than the tumor's location.
Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions.
When first diagnosed with lung cancer, some doctors told Bonnie J. Addario that there was nothing that they could do for her. Now, 14 years later, she has spent over a decade helping others with the disease through her Bonnie J. Addario Lung Cancer Foundation.
A newly developed blood test may identify people at an increased risk for lung cancer, even if they are not within the screening guidelines.
"Scanxiety" is common in people with cancer, but is particularly prevalent in those with lung cancer, according to a recent survey.
Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).
The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.
Five leading cancer organizations came together to establish four steps that patients of all malignancies can turn to as they navigate their experience.
